MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.44
-0.93
-4.35%
Opening 14:42 06/18 EDT
OPEN
21.01
PREV CLOSE
21.37
HIGH
21.27
LOW
20.35
VOLUME
241.47K
TURNOVER
--
52 WEEK HIGH
33.82
52 WEEK LOW
9.12
MARKET CAP
1.63B
P/E (TTM)
-7.9697
1D
5D
1M
3M
1Y
5Y
Merus upgraded on ASCO update, Cantor favors Harpoon after selloff; and more in today’s analyst action
Photo by goir/iStock via Getty Images Merus jumps on Citi upgrade Merus (MRUS) shares have climbed ~5.4% in early trading after Citi analyst Yigal Nochomovitz upgraded the stock to buy from neutral.
Seekingalpha · 06/07 12:49
Alector to Present at Upcoming Virtual Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating office...
GlobeNewswire · 06/03 20:05
Centogene, Alector initiate EFRONT study in frontotemporal dementia
Centogene N.V. (CNTG) announces a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia ((FTD)).The observational EFRONT Study is being conducted with Alector (ALEC)
Seekingalpha · 06/02 10:37
BRIEF-Centogene Initiates EFRONT Study To Identify Patients With Genetic Forms Of Frontotemporal Dementia
reuters.com · 06/02 10:35
CENTOGENE Initiates EFRONT Study To Identify Patients With Genetic Forms Of Frontotemporal Dementia; Study Being Conducted With Support From Alector
Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced a new observational study to understand the prevalence
Benzinga · 06/02 10:34
Centogene Launches Observational Study on Genetic Mutations in Patients With Frontotemporal Dementia
MT Newswires · 06/02 07:26
Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) on Friday...
GlobeNewswire · 05/26 20:05
Ikarian Capital, LLC Buys Eli Lilly and Co, Macrogenics Inc, Galapagos NV, Sells Bristol-Myers ...
GuruFocus News · 05/17 12:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALEC. Analyze the recent business situations of Alector through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALEC stock price target is 32.00 with a high estimate of 41.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 169
Institutional Holdings: 51.08M
% Owned: 64.04%
Shares Outstanding: 79.77M
TypeInstitutionsShares
Increased
33
4.78M
New
15
1.26M
Decreased
44
3.36M
Sold Out
26
2.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.08%
Pharmaceuticals & Medical Research
-1.10%
Key Executives
Chairman/Co-Founder/Director
Tillman Gerngross
President/Chief Operating Officer
Shehnaaz Suliman
Chief Executive Officer/Co-Founder/Director
Arnon Rosenthal
Vice President - Finance
Calvin Yu
Other
Robert King
Other
Robert Paul
Other
Siang-Shu Robert
Lead Director/Independent Director
Louis Lavigne
Independent Director
Paula Hammond
Independent Director
Terry Mcguire
Independent Director
Richard Scheller
Independent Director
Terry McGuire
Independent Director
David Wehner
Independent Director
Kristine Yaffe
No Data
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL002, AL003, and AL101. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.